It’s 2030 and you’ve arrived for your appointment. The clinic looks reassuringly familiar: The treatments on its brochure also appear quite standard: fertility consultations, IVF treatments, genetic counselling, family planning. Nothing about it appears revolutionary at first glance.
Yet behind one discreet door is a service that would have been considered science fiction only a generation ago. This is the ability to edit the genes of future children before they are born. Not to treat disease or to prevent a devastating inherited condition, but to create a designer baby: a child with the intelligence of Elon Musk, the allure of Marilyn Monroe, the grace of Anna Pavlova…
Welcome to the speculative future of reproductive medicine, where the world’s first private gene-editing clinic has opened in London and the era of the designer baby has officially begun. The unsettling reality is that parts of this future have already arrived.
In 2018, Chinese scientist Dr. He Jiankui shocked the world by announcing the birth of twin girls whose embryos had been genetically edited, triggering immediate international condemnation.
A news report in The Guardian explains that He used the gene-editing tool CRISPR-Cas9 to alter embryos created through IVF before they were implanted into a woman’s womb. The embryos developed into twin girls, Lulu and Nana. A third gene-edited child was later reported to have been born as part of the same research programme.
His goal was to disable a gene called CCR5, which produces a protein that HIV uses to enter certain immune cells. People who naturally carry a rare mutation known as CCR5-Δ32 have some resistance to HIV infection.
He hoped that by editing CCR5 in embryos, he could make the children less susceptible to HIV later in life. Importantly, neither child had HIV. The procedure was intended as a preventive enhancement rather than a treatment for an existing disease. This was a distinction which became central to the backlash.
The reaction from the scientific community was swift and overwhelmingly negative. More than 100 Chinese scientists signed a statement condemning the work, while leading researchers around the world described the experiment as irresponsible and premature.
What made the case so significant was that it transformed the ‘designer baby’ debate from a theoretical concern into a real-world event. A line had been crossed and for the first time in human history, genetically edited children had been born, and the technology was no longer theoretical.
In a 2023 article, He reflected on his work, saying: “I did it too quickly.”
He is not alone in shaping the controversy. Cathy Tie is a Canadian entrepreneur and biotechnology founder working at the frontier of human reproductive gene editing. She has built multiple biotech and digital health companies, including early genomics ventures and telemedicine platforms, and positioned herself in the emerging field of embryo editing aimed at preventing inherited disease.
More recently, she has become associated with germline gene editing (the modification of human embryos in ways that can be inherited by future generations). In a 2026 article in The Guardian, she is quoted as saying: “There is no way to stop this.” She is referring to the rapid advancement of genetic editing.
Whether that statement reflects inevitability or provocation remains unclear, but it raises the central question of the debate: Are we witnessing something society can still control, or something already beyond restraint?
The Clinic That Changes Everything
Back to the future… Imagine London in the mid-2030s and the arrival of the clinic that changes everything. On the surface, it offers state-of-the-art treatments, such as futuristic rejuvenation techniques which work at a deep cellular level, leaving patients ‘biologically younger.’ However, alongside longevity therapies sits something far more controversial and this is the option to design a child.
Parents enter to shape outcomes. They want to remove the genetic burdens which have shaped generations, such as diabetes, depression, and other inherited conditions. However, the choices here quickly extend beyond medicine.
Eye colour becomes selectable. Facial structure becomes adjustable. Even temperament is described in marketing terms. For example, on the ‘menu’ for designer child options, a parent can select ‘liquid sunshine’ as a personality option. White-blond hair and sea-blue eyes can complement the summery personality. Features are selected, refined, and ordered.
This transformation does not arrive overnight. It follows years of political and scientific debate, cautious advances in gene-editing safety, and narrow parliamentary approval for regulated commercial germline editing.
Initially, the rules are strict. Clinics are permitted only to eliminate severe inherited diseases such as Huntington’s disease, Tay-Sachs disease, cystic fibrosis, and certain hereditary cancers. The public largely supports this limitation, as no-one should be forced to inherit such suffering.
However, boundaries rarely hold. The history of technology suggests that capabilities rarely remain confined to their original purpose. The internet, originally developed in the 1960s as ARPANET for military communication between research institutions and the U.S. Department of Defense, evolved into a global infrastructure underpinning advertising, political campaigning, and social media ecosystems. Its creators never anticipated this widespread, all-encompassing usage of their technology..
CRISPR-Cas9, first adapted into a programmable gene-editing tool in 2012 by researchers including Jennifer Doudna and Emmanuelle Charpentier, was initially framed as a way to correct single-gene disorders, such as sickle cell disease and cystic fibrosis. Yet within a few years, it had already entered ethical debate after the 2018 announcement of gene-edited babies.
GPS, developed for military navigation and missile targeting, now powers ride-hailing apps, logistics networks, and real-time surveillance economies.
These examples illustrate that once a technology becomes widely available, its use becomes shaped by demand, competition, and economic incentive.
The Transition From Therapy to Enhancement
In this imagined clinic, gene editing begins as prevention but gradually becomes preference.
This is as a result of questions the public and prospective parents might ask, such as: If doctors can remove genes linked to serious illness, why not genes associated with higher disease risk? If they can reduce the chance of heart disease, why not improve resistance to Alzheimer’s? If resistance can be improved, why not cognitive ability? Physical performance? Longevity? Appearance?
Each step feels rational in isolation. However, together, they redefine what it means to be a parent.
Children become designed outcomes rather than inherited chance.
The results of such ‘designing’ might appear modest at first, for example, slightly reduced disease risk, marginal increases in cognitive performance, and small improvements in resilience. However, even marginal advantages can accumulate.
What would more than likely happen is that competition would follow. Education could become more selective and elite careers, harder to access. What began as optional enhancement could become expectation. Parents who refuse genetic editing could risk being seen as disadvantaging their children before birth.
The Question of Choice
The first private clinic in London would not simply represent a new medical service. It would mark a shift in the relationship between humans and biology itself. It would symbolise a transition from chance to choice.
However, in spite of all of the change, this question would remain: Once we gain the ability to choose the traits of future generations, how much choice is too much?
Are we quietly taking God’s role into our own hands? History suggests that when man attempts to replace the moral and natural order with his own design, the results have not ended in perfection, but in collapse. Let man be man. Let God be God.